作者
Takeshi Tsujino, Yutaka Komatsu, Hiroyuki Isayama, Kenji Hirano, Naoki Sasahira, Natsuyo Yamamoto, Nobuo Toda, Yukiko Ito, Yousuke Nakai, Minoru Tada, Masayuki Matsumura, Haruhiko Yoshida, Takao Kawabe, Yasushi Shiratori, Masao Omata
发表日期
2005/4/1
期刊
Clinical Gastroenterology and Hepatology
卷号
3
期号
4
页码范围
376-383
出版商
WB Saunders
简介
Background & Aims
Pancreatitis remains the major complication of endoscopic retrograde cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Because ulinastatin, a protease inhibitor, has proved effective in the treatment of acute pancreatitis, the aim of this study was to assess the efficacy of ulinastatin for the prevention of post-ERCP pancreatitis and hyperenzymemia.
Methods
In a multicenter, randomized, double-blind, placebo-controlled trial, patients undergoing a first ERCP were randomized to receive ulinastatin (150,000 U) or placebo by intravenous infusion for 10 minutes starting immediately before ERCP. All patients were hospitalized at least 24 hours after ERCP for evaluation of clinical symptoms. Serum pancreatic enzyme levels were measured before and at 4 and 18 hours after ERCP. The primary end point was the incidence of post-ERCP pancreatitis and the secondary …
引用总数
学术搜索中的文章
T Tsujino, Y Komatsu, H Isayama, K Hirano, N Sasahira… - Clinical Gastroenterology and Hepatology, 2005